[Evaluation of anti-androgen therapy for benign prostatic hypertrophy by using transrectal prostatic ultrasonography].
We evaluated the effect of anti-androgen therapy for benign prostatic hypertrophy on 33 patients who had undergone transrectal prostatic ultrasonography both before and after administration of anti-androgenic drugs in our clinic. Patients treated with chlormadinone acetate (CMA) orally, or TSAA-291 intramuscularly showed a significant reduction in the prostatic weight. However, this reduction was not correlated with the degree of symptomatic improvement. In addition, patients who showed no symptomatic improvement despite a reduction in the prostatic weight often had prostatic stones or small inflammatory cell infiltrations in their prostatic tissue. Therefore, the coexistence of prostatitis or bladder neck obstruction with prostatic hypertrophy may contribute to the lack of symptomatic improvement in such patients.
Kazama
T
T
Department of Urology, School of Medicine, Toyama Medical and Pharmaceutical University.
Mizuno
I
I
Takamine
T
T
Umeda
K
K
Terada
T
T
Ishikawa
S
S
Fuse
H
H
Katayama
T
T
D000284:Administration, Oral; D000726:Androgen Antagonists / Q000627:therapeutic use*; D002715:Chlormadinone Acetate / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011467:Prostate / Q000000981:diagnostic imaging*; D011470:Prostatic Hyperplasia / Q000000981:diagnostic imaging / Q000188:drug therapy*; D014463:Ultrasonography / Q000379:methods
D000726:Androgen Antagonists; D002715:Chlormadinone Acetate; D009277:Nandrolone; C005671:oxendolone